Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats

Pharmacology Biochemistry and Behavior

Volumn 61, Issue 3, 1998, Pages 215-220

  De Sarro, Giovambattista ^a,c   Rizzo, Milena ^a   Sinopoli, Vincenzo Antonio ^a   Gitto, Rosaria ^b   De Sarro, Angela ^b   Zappala, Maria ^b   Chimirri, Alba ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Dept of Exp and Clinical Medicine ^*  (Italy)

Author keywords

2,3 Benzodiazepine; AMPA kainate antagonists; Epilepsy; Genetically epilepsy prone rats; Plasma level

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 3,5 DIHYDRO 7,8 DIMETHOXY 1 PHENYL 4H 2,3 BENZODIAZEPIN 4 ONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GRAND MAL EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; EPILEPSY; MOTOR ACTIVITY; MOTOR SKILLS DISORDERS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA;

EID: 0031764446     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00036-7     Document Type: Article

References (30)

1. Buchan, A. M.; Li, H.; Cho, S.; Pulsinelli, W. A.: Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transiet forebrain ischemia in adult rats. Neurosci. Lett. 132:255-258; 1991.
2. Chapman, A. G.; Smith, S. E.; Meldrum, B. S.: The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466 in mice. Epilepsy Res. 9:92-96; 1991.
3. Chimirri, A.; De Sarro, G. B.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappalà, M.; Giusti, P.; Libri, V.; Constanti, A.; Chapman, A. G.: 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: Novel AMPA receptor antagonists. J. Med. Chem. 40:1258-1269; 1997.
4. De Sarro, G. B.; Chimirri, A.; De Sarro, A.; Gitto, R.; Grasso, S.; Giusti, P.; Chapman, A. G.: GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J. Pharmacol. 294:411-422; 1995.
5. De Sarro, G. B.; Chimirri, A.; De Sarro, A.; Gitto, R.; Grasso, S.; Zappalà, M.; Rizzo, M.; Chapman, A.: Anticonvulsant properties of new 2,3-benzodiazepines in mice. Fundam. Clin. Pharmacol. 10:184; 1996.
6. De Sarro, A.; De Sarro, G. B.: Responsiveness of genetically epilepsy prone rats to aminophylline-induced seizures and interactions with quinolones. Neuropharmacology 30:169-176; 1991.
7. De Sarro, G. B.; De Sarro, A.: Anticonvulsant activity of competitive antagonists of NMDA receptor in genetically epilepsy prone rats. Eur. J. Pharmacol. 215:221-229; 1992.
8. De Sarro, G. B.; De Sarro, A.: Anticonvulsant properties of non competitive antagonists of NMDA receptor in genetically epilepsy prone rats. Comparison with CPPene. Neuropharmacology 32:51-58; 1993.
9. De Sarro, G. B.; Ongini, E.; Bertorelli, R.; Aguglia, U.; De Sarro, A.: Excitatory amino acid neurotransmission through both NMDA and nonNMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur. J. Pharmacol. 262:11-19; 1994.
10. De Sarro, G. B.; Donato Di Paola, E.; Aguglia, U.; De Sarro, A.: Tolerance to anticonvulsant effects of clobazam, diazepam and clonazepam in genetically epilepsy prone rats. Pharmacol. Biochem. Behav. 55:39-48; 1996.
11. De Sarro, A.; Trimarchi, G. R.; Ammendola, D.; De Sarro, G. B.: Repetitive treatment with quinolones potentiates the seizures induced by aminophylline in genetically epilepsy-prone rats. Gen. Pharmacol. 23:853-859; 1992.
12. De Sarro, G. B.; Trimarchi, G. R.; Sinopoli, S.; Masuda, Y.; De Sarro, A.: Anticonvulsant effects of U-54494A and U-50488H in genetically epilepsy-prone rats and DBA/2 mice: A possible involvement of glycine/NMDA receptor complex. Gen. Pharmacol. 24:439-447; 1993.
13. Dunham, N. W.; Miya T. S.: A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46:208-209; 1957.
14. Frank, L.; Bruhn, T.; Diemer, N. H.: Regional cerebral protein synthesis after transient ischemia in the rat: Effect of the AMPA antagonist NBQX. Neurosci. Lett. 140:108-112; 1992.
15. Gean, P. W.: The epileptiform activity induced by 4-aminopyridine in rat amygdala slices: Antagonism by non-N-methyl-D-aspartate receptor antagonists. Brain Res. 530:251-256; 1990.
16. Jobe, P. C.: Pharmacology of audiogenic seizures. In: Brown, R. D.; Daigneault, E. A., eds. Pharmacology of hearing. Experiment and clinical bases. New York: John Wiley; 1981:271-304.
17. Klockgether, T.; Turski, L.; Honore, T.; Zhang, Z. M.; Gash, D. M.; Kurlan, R.; Greenamyre, J. T.: The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30:717-723; 1991.
18. Litchfield, J. F.; Wilcoxon, F.: A simplified method of evaluating dose-effects experiments. J. Pharmacol. Exp. Ther. 96:99-113; 1949.
19. Meldrum, B. S.; Millan, M.; Patel, S.; De Sarro, G. B.: Anti-epileptic effects of focal micro-injection of excitatory amino acid antagonists. J. Neural Transm. 72:191-198; 1988.
20. Rainnie, D. G.; Asprodini, E. K.; Shinnick-Gallagher, P.: Kindling-induced long-lasting changes in synaptic transmission in the basolateral amygdala. J. Neurophysiol. 67:443-454; 1992.
21. Rizzo, M.; Sinopoli, V. A.; Gitto, R.; Zappalà, M.; De Sarro, G. B.; Chimirri, A.: High-performance liquid chromatographic determination of new 2,3-benzodiazepines. J. Chromatogr. B. 705:149-153; 1998.
22. Rogawski, M.: Therapeutic potential of excitatory amino acid antagonists: Channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14:325-331; 1993.
23. Sheardown, M. J.; Nielsen, E. O.; Hansen, A. J.; Jacobsen, P.; Honore, T.: 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline: A neuroprotectant for cerebral ischemia. Science 247:571-574; 1991.
24. Smith, S. E.; Durmuller, N.; Meldrum, B. S.: The non-N-methyl-D-aspartate antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:179-183; 1991.
25. Smith, S. E.; Meldrum, B. S.: Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke 23:861-864; 1992.
26. Tarnawa, I.; Farkas, S.; Berzsenyi, P.; Pataki, A.; Andreasi, F.: Electrophysiological studies with 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol. 167:193-199; 1989.
27. Tarnawa, I.; Engberg, I.; Flatman, J. A.: GYKI 52466 an inhibitor of spinal reflexes is a potent quisqualate antagonist. In: Lube, G.; Resental, G. A., eds. Amino acids: Chemistry, biology and medicine. Escona: Leiden; 1990:538-546.
28. Wachtel, H.; Kunow, M.; Loeschman, P. A.: NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazinpropyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett. 142:179-182; 1992.
29. Westergren, I.; Johansson, B. B.: NBQX, an AMPA antagonist, reduces glutamate-mediated brain edema. Brain Res. 573:324-326; 1992.
30. Yamaguchi, S.; Donevan, S. D.; Rogawski, M. A.: Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:179-184; 1993.